SI3307322T1 - Humanizirana protitelesa proti CD40 in njihove uporabe - Google Patents
Humanizirana protitelesa proti CD40 in njihove uporabeInfo
- Publication number
- SI3307322T1 SI3307322T1 SI201631164T SI201631164T SI3307322T1 SI 3307322 T1 SI3307322 T1 SI 3307322T1 SI 201631164 T SI201631164 T SI 201631164T SI 201631164 T SI201631164 T SI 201631164T SI 3307322 T1 SI3307322 T1 SI 3307322T1
- Authority
- SI
- Slovenia
- Prior art keywords
- humanized antibodies
- humanized
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562214411P | 2015-09-04 | 2015-09-04 | |
| PCT/US2016/050114 WO2017040932A1 (en) | 2015-09-04 | 2016-09-02 | Humanized anti-cd40 antibodies and uses thereof |
| EP16843066.8A EP3307322B1 (en) | 2015-09-04 | 2016-09-02 | Humanized anti-cd40 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3307322T1 true SI3307322T1 (sl) | 2021-08-31 |
Family
ID=58188471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201631164T SI3307322T1 (sl) | 2015-09-04 | 2016-09-02 | Humanizirana protitelesa proti CD40 in njihove uporabe |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US9974855B2 (enExample) |
| EP (2) | EP3906943A1 (enExample) |
| JP (3) | JP6976931B2 (enExample) |
| KR (2) | KR102779818B1 (enExample) |
| CN (2) | CN109069621B (enExample) |
| AU (2) | AU2016315873B2 (enExample) |
| BR (1) | BR112018004296B1 (enExample) |
| CA (1) | CA3002789A1 (enExample) |
| DK (1) | DK3307322T3 (enExample) |
| ES (1) | ES2887602T3 (enExample) |
| HU (1) | HUE056769T2 (enExample) |
| MX (2) | MX2018002708A (enExample) |
| PL (1) | PL3307322T3 (enExample) |
| PT (1) | PT3307322T (enExample) |
| SI (1) | SI3307322T1 (enExample) |
| WO (1) | WO2017040932A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2683406T (pt) | 2011-03-11 | 2019-07-08 | Beth Israel Deaconess Medical Ct Inc | Anticorpos anti-cd40 e utilização dos mesmos |
| EP3229586B1 (en) | 2014-12-10 | 2025-07-30 | Regents of the University of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| HUE056769T2 (hu) * | 2015-09-04 | 2022-03-28 | Primatope Therapeutics Inc | Humanizált anti-CD40 antitestek és felhasználásuk |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| JP2020504105A (ja) | 2016-12-19 | 2020-02-06 | グレンマーク・ファーマシューティカルズ・エスエー | 新規なｔｎｆｒアゴニストおよびその使用 |
| US11525005B2 (en) | 2017-06-01 | 2022-12-13 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof |
| WO2019156565A1 (en) | 2018-02-12 | 2019-08-15 | Fast Forward Pharmaceuticals B.V. | Improved antagonistic anti-human cd40 monoclonal antibodies |
| KR102728939B1 (ko) | 2018-07-20 | 2024-11-11 | 유큐(베이징) 바이오파마 코., 엘티디 | 항-cd40 항체 및 그의 용도 |
| MX2021006360A (es) | 2018-11-30 | 2021-08-11 | Jiangsu Hengrui Medicine Co | Composicion farmaceutica de anticuerpo cd40 y uso de la misma. |
| BR112021009835A2 (pt) | 2018-11-30 | 2021-08-17 | Jiangsu Hengrui Medicine Co., Ltd. | anticorpo anti-cd40, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos |
| WO2020154627A1 (en) | 2019-01-25 | 2020-07-30 | Promab Biotechnologies, Inc. | Epcam antibody and epcam-car-t cells |
| CN113728008B (zh) * | 2019-04-10 | 2024-04-09 | 南开大学 | 抗cd40抗体及其用途 |
| AU2020267953A1 (en) * | 2019-05-08 | 2021-11-18 | Novartis Ag | Anti-CD40 antibodies for use in treatment of T1DM and insulitis |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
| WO2020253722A1 (en) * | 2019-06-17 | 2020-12-24 | Eucure (Beijing) Biopharma Co., Ltd | Anti-cd40 antibodies and uses thereof |
| CA3148890A1 (en) * | 2019-09-11 | 2021-03-18 | Novartis Ag | A method for preventing human virus associated disorders in patients |
| WO2021213245A1 (zh) * | 2020-04-20 | 2021-10-28 | 上海翰森生物医药科技有限公司 | 抗体或其抗原结合片段、其制备方法及医药用途 |
| EP4153630A1 (en) * | 2020-05-18 | 2023-03-29 | Bristol-Myers Squibb Company | Antibody variants with improved pharmacokinetic properties |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| WO2022251253A1 (en) | 2021-05-24 | 2022-12-01 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| EP4365200A4 (en) * | 2021-06-28 | 2025-04-09 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | ANTI-CD40 ANTIBODY, ANTIGEN-BINDING FRAGMENT AND MEDICAL USE THEREOF |
| CN115768477A (zh) * | 2021-06-29 | 2023-03-07 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别cd40的抗体及其应用 |
| KR20240058075A (ko) * | 2021-07-14 | 2024-05-03 | 스테이드슨 (베이징) 바이오팔마슈티칼스 캄퍼니 리미티드 | Cd40을 특이적으로 식별하는 항체 및 이의 응용 |
| JP7732839B2 (ja) * | 2021-10-14 | 2025-09-02 | 株式会社三共 | 遊技機 |
| JP7732840B2 (ja) * | 2021-10-14 | 2025-09-02 | 株式会社三共 | 遊技機 |
| JP7732841B2 (ja) * | 2021-10-14 | 2025-09-02 | 株式会社三共 | 遊技機 |
| JP7732843B2 (ja) * | 2021-10-14 | 2025-09-02 | 株式会社三共 | 遊技機 |
| JP7732842B2 (ja) * | 2021-10-14 | 2025-09-02 | 株式会社三共 | 遊技機 |
| JP2024540377A (ja) * | 2021-11-05 | 2024-10-31 | キニクサ・ファーマシューティカルズ，ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ヒト化抗ｃｄ４０抗体の医薬組成物 |
| US12234294B2 (en) * | 2021-11-05 | 2025-02-25 | Kiniksa Pharmaceuticals, Gmbh | Pharmaceutical composition of a humanized anti-CD40 antibody |
| JP2024542148A (ja) * | 2021-11-05 | 2024-11-13 | キニクサ・ファーマシューティカルズ，ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ヒト化抗ｃｄ４０抗体の医薬組成物およびその使用 |
| JP2025502095A (ja) * | 2022-01-10 | 2025-01-24 | キニクサ・ファーマシューティカルズ，ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 移植拒絶反応のリスクを処置または低減する方法 |
| WO2024107752A2 (en) | 2022-11-15 | 2024-05-23 | Onestone Therapeutics Llc | Compositions and methods for immunomodulatory bifunctional fusion molecules |
| WO2025045766A1 (en) | 2023-08-25 | 2025-03-06 | Kiniksa Pharmaceuticals, Gmbh | Compositions comprising humanized anti-cd40 antibodies and methods for treating rheumatoid arthritis using the same |
| US20260022185A1 (en) | 2024-01-03 | 2026-01-22 | Kiniksa Pharmaceuticals, Gmbh | Method of reducing aggregation in the virus-inactivated preparation of anti-cd40 antibodies |
| WO2025169146A1 (en) | 2024-02-09 | 2025-08-14 | Kiniksa Pharmaceuticals, Gmbh | Cd40 antagonist or cd154 antagonist for use in mitigating immune responses in protein and gene therapies |
| US20250277048A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
Family Cites Families (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3737433A (en) | 1964-09-05 | 1973-06-05 | Albert Ag Chem Werke | Certain oxoalkyldimethylxanthines |
| DE2819094A1 (de) | 1977-05-10 | 1978-11-23 | Sandoz Ag | Cyclosporin-derivate, ihre verwendung und herstellung |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| SE445174B (sv) | 1978-03-07 | 1986-06-09 | Sandoz Ag | Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans |
| DE3260468D1 (en) | 1981-01-09 | 1984-09-06 | Sandoz Ag | Novel cyclosporins |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4576284A (en) | 1983-12-02 | 1986-03-18 | Warner-Lambert Company | Closing of filled capsules |
| US4894366A (en) | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
| CH667274A5 (de) | 1984-03-23 | 1988-09-30 | Sandoz Ag | Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen. |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| EP0247091B1 (en) | 1985-11-01 | 1993-09-29 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8611905D0 (en) | 1986-05-15 | 1986-06-25 | Lilly Industries Ltd | Capsules |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| GB8729153D0 (en) | 1987-12-14 | 1988-01-27 | Efamol Ltd | Fatty acid compositions |
| DE68900991D1 (de) | 1988-01-29 | 1992-04-23 | Sankyo Co | Cyclosporin-zusammensetzungen. |
| HU201567B (en) | 1988-07-21 | 1990-11-28 | Gyogyszerkutato Intezet | Process for production of intravenous medical compositions containing cyclosphorin |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3919982A1 (de) | 1989-06-19 | 1990-12-20 | Liedtke Pharmed Gmbh | Orale lipidarzneiform |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| JPH04230389A (ja) | 1990-07-16 | 1992-08-19 | American Home Prod Corp | ラパマイシン誘導体 |
| US5023262A (en) | 1990-08-14 | 1991-06-11 | American Home Products Corporation | Hydrogenated rapamycin derivatives |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| PT98990A (pt) | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
| GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
| US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
| US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
| US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
| US5120725A (en) | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Bicyclic rapamycins |
| US5120727A (en) | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Rapamycin dimers |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US5164495A (en) | 1991-09-18 | 1992-11-17 | Abbott Laboratories | Method for preparing a dicarboxylic acid half-acid ester of FK506 |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
| GB9125660D0 (en) | 1991-12-03 | 1992-01-29 | Smithkline Beecham Plc | Novel compound |
| US5177203A (en) | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
| US5874082A (en) | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| US5234140A (en) | 1992-07-28 | 1993-08-10 | S. C. Johnson & Son, Inc. | Re-useable aerosol container |
| US5256790A (en) | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
| AU687755B2 (en) | 1992-08-21 | 1998-03-05 | Genentech Inc. | Method for treating an LFA-1-mediated disorder |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| KR960704576A (ko) | 1993-10-01 | 1996-10-09 | 크리스토퍼 엘. 와이트 | CD40에 대한 항체(Antibodies to CD40) |
| WO1995014023A1 (en) | 1993-11-19 | 1995-05-26 | Abbott Laboratories | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
| US5908635A (en) | 1994-08-05 | 1999-06-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the liposomal delivery of nucleic acids |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| US6096716A (en) | 1994-12-12 | 2000-08-01 | The Board Of Regents, The University Of Texas System | Liposome-mediated transfection of central nervous system cells |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5827822A (en) | 1996-03-25 | 1998-10-27 | Sangstat Medical Corporation | Cyclosporin a formulations as nanoparticles |
| US5766629A (en) | 1995-08-25 | 1998-06-16 | Sangstat Medical Corporation | Oral cyclosporin formulations |
| US20030099642A1 (en) | 1996-04-22 | 2003-05-29 | Michael J. Yellin | Therapeutic applications for the anti-t-bam (cd40l) monoclonal antibody 5c8 in the treatment of vasculitis |
| WO1997022256A1 (en) | 1995-12-19 | 1997-06-26 | National Jewish Center For Immunology And Respiratory Medicine | Method to regulate cd40 signaling |
| AUPO517897A0 (en) | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
| CA2319448A1 (en) | 1998-02-04 | 1999-08-12 | The General Hospital Corporation | Costimulatory blockade and mixed chimerism in allotransplantation |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| AUPP807399A0 (en) | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
| ES2572834T3 (es) | 1999-02-17 | 2016-06-02 | Csl Limited | Complejos inmunogénicos y métodos relacionados con los mismos |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| AU2001236621B2 (en) | 2000-02-01 | 2006-06-15 | Mycenax Biotech Inc. | Cd40-binding apc-activating molecules |
| BR0110190A (pt) | 2000-04-19 | 2003-12-30 | Tanox Inc | Antagonistas de cd40 para uso em tratamento de psorìase e outras condições inflamatórias de pele |
| US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
| DK1297017T3 (da) | 2000-06-19 | 2012-09-17 | Dana Farber Cancer Inst Inc | Sammensætninger og fremgangsmåder med monoklonale og polyklonale antistoffer, der er specifikke for T-cellesubpopulationer |
| WO2002028905A2 (en) | 2000-10-02 | 2002-04-11 | Chiron Corporation | Human anti-cd40 antibodies |
| EP2011802A3 (en) | 2001-04-27 | 2009-04-15 | Kyowa Hakko Kirin Co., Ltd. | Anti-CD40 monoclonal antibody |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US20040126829A1 (en) | 2001-12-18 | 2004-07-01 | Hildebrand William H. | Anti-HLA assay and methods |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| JP4746552B2 (ja) | 2003-11-04 | 2011-08-10 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 自己免疫疾患および炎症性疾患ならびに臓器移植拒絶の処置のためのアンタゴニスト抗ｃｄ４０抗体の使用 |
| ES2346978T3 (es) | 2003-11-04 | 2010-10-22 | Novartis Vaccines And Diagnostics, Inc. | Uso de anticuerpos monoclonantes anti-cd40 antagonistas para el tratamiento del mieloma multiple. |
| WO2005044307A2 (en) | 2003-11-04 | 2005-05-19 | Chiron Corporation | Methods of therapy for b cell-related cancers |
| CA2544364A1 (en) | 2003-11-04 | 2005-05-19 | Chiron Corporation | Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| KR101223373B1 (ko) | 2003-12-25 | 2013-01-16 | 교와 핫꼬 기린 가부시키가이샤 | 항 ｃｄ４０ 항체의 변이체 |
| EP2857418B1 (en) | 2004-02-06 | 2017-07-26 | University of Massachusetts | Antibodies against Clostridium difficile toxins and uses thereof |
| AU2005323515A1 (en) * | 2004-04-27 | 2006-07-13 | Novartis Vaccines And Diagnostics, Inc. | Antagonist anti-CD40 monoclonal antibodies and methods for their use |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| AU2005333126A1 (en) | 2004-07-18 | 2006-12-21 | Csl Limited | Methods and compositions for inducing innate immune responses |
| CA2572427A1 (en) | 2004-07-18 | 2006-01-18 | Heather L. Davis | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
| CA2580981C (en) | 2004-09-22 | 2013-10-22 | Kirin Beer Kabushiki Kaisha | Stabilized human igg4 antibodies |
| ES2453973T3 (es) | 2005-02-02 | 2014-04-09 | University Of Massachusetts | Anticuerpos humanos contra la rabia y usos de los mismos |
| EP1885399B1 (en) | 2005-05-26 | 2010-10-20 | Seattle Genetics, Inc. | Humanized anti-cd40 antibodies and their methods of use |
| WO2006133450A2 (en) | 2005-06-08 | 2006-12-14 | Duke University | Anti-cd19 antibody therapy for the transplantation |
| JP2009517339A (ja) | 2005-11-01 | 2009-04-30 | ノバルティス アーゲー | 抗ｃｄ４０抗体の使用 |
| JP2009513712A (ja) | 2005-11-01 | 2009-04-02 | ノバルティス アーゲー | 抗ｃｄ４０抗体の使用 |
| AU2006329944A1 (en) * | 2005-12-09 | 2007-07-05 | Seattle Genetics, Inc. | Methods of using CD40 binding agents |
| GEP20125628B (en) | 2006-04-21 | 2012-09-10 | Novartis Ag | Pharmaceutical compositions containing antagonist anti-cd40 antibody |
| EP1854810A1 (en) | 2006-05-09 | 2007-11-14 | PanGenetics B.V. | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
| EP2073785B1 (en) | 2006-09-29 | 2018-05-30 | Union Carbide Chemicals & Plastics Technology Corporation | Quaternized cellulose ethers for personal care products |
| SG196697A1 (en) | 2007-03-22 | 2014-02-13 | Biogen Idec Inc | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof |
| CN101970003A (zh) | 2007-11-09 | 2011-02-09 | 诺华有限公司 | 抗cd40抗体的应用 |
| EP2245065A1 (en) | 2008-01-23 | 2010-11-03 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| JP2012511014A (ja) | 2008-12-05 | 2012-05-17 | エイエルエス・セラピー・デベロップメント・インスティテュート | 神経変成疾患を治療する方法 |
| AU2010222942B2 (en) | 2009-03-10 | 2013-01-10 | Baylor Research Institute | Anti-CD40 antibodies and uses thereof |
| NZ602020A (en) | 2010-03-31 | 2014-05-30 | Boehringer Ingelheim Int | Anti-cd40 antibodies |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| JP5458188B2 (ja) | 2011-02-17 | 2014-04-02 | 協和発酵キリン株式会社 | 抗ｃｄ４０抗体の高濃度製剤 |
| PT2683406T (pt) | 2011-03-11 | 2019-07-08 | Beth Israel Deaconess Medical Ct Inc | Anticorpos anti-cd40 e utilização dos mesmos |
| US9475879B2 (en) | 2011-04-21 | 2016-10-25 | Bristol-Myers Squibb Company | Antibody polypeptides that antagonize CD40 |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| US10533054B2 (en) | 2013-01-31 | 2020-01-14 | Thomas Jefferson University | Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system |
| CN112245586A (zh) | 2013-03-15 | 2021-01-22 | 小利兰·斯坦福大学托管委员会 | 用于实现治疗有效剂量的抗cd47剂的方法 |
| GB201501613D0 (en) | 2015-01-30 | 2015-03-18 | Ucb Biopharma Sprl | Treatment of autoimmune disorders with CD154 antibodies |
| MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| WO2016199146A1 (en) | 2015-06-09 | 2016-12-15 | B. G. Negev Technologies And Applications Ltd | A controlled release system for pulmonary delivery of surfactant protein d |
| KR102671348B1 (ko) | 2015-06-29 | 2024-05-30 | 브리스톨-마이어스 스큅 컴퍼니 | Cd40에 대한 항체 |
| HUE056769T2 (hu) | 2015-09-04 | 2022-03-28 | Primatope Therapeutics Inc | Humanizált anti-CD40 antitestek és felhasználásuk |
| CN113039203A (zh) | 2018-10-18 | 2021-06-25 | 中国抗体制药有限公司 | 通过破坏siglec型抗原的顺式配体结合调节自身免疫的方法 |
| JP2023542678A (ja) | 2020-09-21 | 2023-10-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 炎症状態の処置のための抗ｃｄ４０抗体の使用。 |
| WO2023044048A1 (en) | 2021-09-17 | 2023-03-23 | Novartis Ag | Methods for prevention of graft rejection in xenotransplantation |
| JP2024542148A (ja) | 2021-11-05 | 2024-11-13 | キニクサ・ファーマシューティカルズ，ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ヒト化抗ｃｄ４０抗体の医薬組成物およびその使用 |
| WO2023081831A2 (en) | 2021-11-05 | 2023-05-11 | Diabetes-Free, Inc. | Methods and compositions for immune tolerance to aav antigens and transgene products in gene therapy |
| JP2024540377A (ja) | 2021-11-05 | 2024-10-31 | キニクサ・ファーマシューティカルズ，ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ヒト化抗ｃｄ４０抗体の医薬組成物 |
| US12234294B2 (en) | 2021-11-05 | 2025-02-25 | Kiniksa Pharmaceuticals, Gmbh | Pharmaceutical composition of a humanized anti-CD40 antibody |
| JP2025502095A (ja) | 2022-01-10 | 2025-01-24 | キニクサ・ファーマシューティカルズ，ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 移植拒絶反応のリスクを処置または低減する方法 |
| WO2025045766A1 (en) | 2023-08-25 | 2025-03-06 | Kiniksa Pharmaceuticals, Gmbh | Compositions comprising humanized anti-cd40 antibodies and methods for treating rheumatoid arthritis using the same |
| WO2025169146A1 (en) | 2024-02-09 | 2025-08-14 | Kiniksa Pharmaceuticals, Gmbh | Cd40 antagonist or cd154 antagonist for use in mitigating immune responses in protein and gene therapies |
-
2016
- 2016-09-02 HU HUE16843066A patent/HUE056769T2/hu unknown
- 2016-09-02 PT PT168430668T patent/PT3307322T/pt unknown
- 2016-09-02 MX MX2018002708A patent/MX2018002708A/es unknown
- 2016-09-02 DK DK16843066.8T patent/DK3307322T3/da active
- 2016-09-02 EP EP21156562.7A patent/EP3906943A1/en active Pending
- 2016-09-02 PL PL16843066T patent/PL3307322T3/pl unknown
- 2016-09-02 EP EP16843066.8A patent/EP3307322B1/en active Active
- 2016-09-02 KR KR1020187009524A patent/KR102779818B1/ko active Active
- 2016-09-02 ES ES16843066T patent/ES2887602T3/es active Active
- 2016-09-02 AU AU2016315873A patent/AU2016315873B2/en active Active
- 2016-09-02 KR KR1020247043041A patent/KR20250007054A/ko active Pending
- 2016-09-02 CN CN201680064574.2A patent/CN109069621B/zh active Active
- 2016-09-02 CN CN202211072946.XA patent/CN116063481A/zh active Pending
- 2016-09-02 BR BR112018004296A patent/BR112018004296B1/pt active IP Right Grant
- 2016-09-02 JP JP2018512313A patent/JP6976931B2/ja active Active
- 2016-09-02 SI SI201631164T patent/SI3307322T1/sl unknown
- 2016-09-02 WO PCT/US2016/050114 patent/WO2017040932A1/en not_active Ceased
- 2016-09-02 CA CA3002789A patent/CA3002789A1/en active Pending
-
2017
- 2017-12-01 US US15/829,352 patent/US9974855B2/en active Active
-
2018
- 2018-03-02 MX MX2022015631A patent/MX2022015631A/es unknown
- 2018-04-17 US US15/955,393 patent/US10201608B2/en active Active
- 2018-12-27 US US16/234,110 patent/US10772958B2/en active Active
-
2020
- 2020-08-14 US US16/994,249 patent/US11439706B2/en active Active
-
2021
- 2021-07-20 JP JP2021119613A patent/JP7763612B2/ja active Active
-
2022
- 2022-08-08 US US17/818,188 patent/US12514924B2/en active Active
- 2022-10-04 AU AU2022241635A patent/AU2022241635A1/en not_active Abandoned
-
2023
- 2023-05-22 JP JP2023084151A patent/JP2023103460A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL278803A (en) | PD-1 antibody molecules and their use | |
| SI3221363T1 (sl) | Protitelesa proti CD73 in njihova uporaba | |
| NL301167I2 (nl) | Lumasiran | |
| SI3215532T1 (sl) | Protitelesa proti TIM3 in postopki uporabe | |
| IL254734B1 (en) | Modified t cells and methods of making and using the same | |
| PL3148579T3 (pl) | Przeciwciała anty-gitr i sposoby ich zastosowania | |
| IL251970B (en) | Anti-cd79b antibodies and methods of use | |
| SI3274370T1 (sl) | Protitelesa proti CEACAM6 in njihova uporaba | |
| IL248741A0 (en) | Compositions and methods for reducing pathogen-induced citrus greening | |
| SI3258951T1 (sl) | Anti-pvrig protitelesa in metode uporabe | |
| SG11201605627TA (en) | Antibody molecules to tim-3 and uses thereof | |
| SI3380522T1 (sl) | Molekule protitelesa proti APRIL in uporabe le-teh | |
| KR20180084891A (ko) | 구조 조성물 및 방법 | |
| DK3152607T3 (da) | En antiresonant hulkernefiber | |
| LT3097119T (lt) | Žmogaus antikūnai prieš pd-1 | |
| EP3636073C0 (en) | HUMANIZED C5 AND C3 ANIMALS | |
| DK3333191T3 (da) | Anti-C10ORF54-antistoffer og anvendelser deraf | |
| ME03558B (me) | Molekuli anti-lag-3 antiтela i njihove upotrebe | |
| DK3126388T3 (da) | Anti-EGFRvIII-antistoffer og anvendelser deraf | |
| MA40933A (fr) | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines | |
| SI3394065T1 (sl) | Tetrahidropiranil amino-pirolopirimidinon in postopki za uporabo le-tega | |
| HRP20251683T1 (hr) | Humanizirana anti-acth antitijela i njihova uporaba | |
| DK3015526T3 (da) | Hydrofluorolefinbaseret sammensætning og anvendelse deraf | |
| SI3280440T1 (sl) | Humanizirana protitelesa proti C1S in načini uporabe | |
| IL259202A (en) | Modified immune cells and uses thereof |